Oncology Institute, Inc. 8-K

What Happened

• The Oncology Institute announced by Unanimous Written Consent that Mark D. Stolper was appointed to its Board of Directors effective January 2, 2026.
• The Board named Mr. Stolper Chair of the Audit Committee and designated him as the Audit Committee financial expert after vetting him through the Nominating and Corporate Governance Committee.
• His term runs until the Company’s next annual meeting of stockholders, at which time he is expected to be nominated as part of management’s slate.

Key Details

• Appointment effective date: January 2, 2026; press release issued January 5, 2026 (Exhibit 99.1).
• Independence: Board concluded Mr. Stolper meets Nasdaq independence requirements.
• Compensation: Non-employee director cash pay of $75,000 per year (paid quarterly) plus restricted stock units (RSUs) to be granted later for Board and Audit Committee service.
• No related-party arrangements or reportable transactions under Item 404(a) were disclosed.

Why It Matters

• Adding an independent Audit Committee Chair and a designated financial expert strengthens the Board’s oversight of financial reporting and internal controls—an area investors watch closely.
• The appointment fills a Board vacancy and will be subject to shareholder vote at the next annual meeting, so it affects Board composition and governance going forward.
• The disclosed cash and equity compensation give investors clarity on the expected cost of this Board addition.